<DOC>
	<DOCNO>NCT00869752</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , MK-0646 , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , etoposide cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I/II trial study side effect best dose MK-0646 give together etoposide cisplatin see well work treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>MK-0646 , Etoposide , Cisplatin Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine recommended phase II dose MK-0646 combination standard etoposide cisplatin chemotherapy regimen patient extensive stage small cell lung cancer . ( phase I ) - To assess toxicity tolerability regimen patient . ( phase I II ) - To evaluate preliminary efficacy regimen patient . ( phase I ) - To assess efficacy regimen , term objective response rate , well complete response rate patient . ( phase II ) - To assess progression-free survival overall survival patient treat regimen . ( phase II ) - To explore predictive prognostic impact biomarkers patient treat regimen . ( phase II ) OUTLINE : This multicenter , phase I , dose-escalation study MK-0646 follow phase II study . Patients receive MK-0646 IV 1 hour day 1 , 8 , 15 cisplatin IV etoposide IV daily day 1-3 . Treatment repeat every 3 week 4 8 course absence disease progression unacceptable toxicity . After completion study treatment , patient complete response ( CR ) partial response ( PR ) may continue MK-0646 absence disease progression , temporary discontinuation undergo prophylactic cranial irradiation thoracic radiotherapy . Blood sample collect baseline ( pre-dose ) periodically biomarker pharmacogenetic correlative study . Blood sample analyze change expression IGF biomarkers ( e.g. , IGF-1 , IGF-2 IGF-PB ) , haplotype tag analysis IGF-1R , evaluation immunoglobulin G fragment C receptor polymorphism . After completion study therapy , patient follow 4 week . Patients respond disease ( i.e. , CR , PR , stable disease ) follow every 3 month relapse progression .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer ( SCLC ) Extensive stage disease incurable amenable treatment platinumbased chemotherapy Small cell variant histology allow No mixed tumor ( i.e. , small large cell ) neuroendocrine tumor lung Clinically and/or radiologically document measurable disease , define ≥ 1 unidimensionally measurable site disease ≥ 20 mm chest xray , ≥ 15 mm CT scan ( lymph node ) , ≥ 10 mm CT scan physical exam No uncontrolled symptomatic CNS metastases Patients complete radiotherapy undergone complete resection CNS metastases allow provide stable ( nonincreasing ) decrease dos corticosteroid PATIENT CHARACTERISTICS : Life expectancy ≥ 12 week ECOG performance status 02 Absolute granulocyte count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ upper limit normal ( ULN ) AST ALT ≤ 3 time ULN ( ≤ 5 time ULN document liver metastasis ) Serum creatinine ≤ ULN OR creatinine clearance ≥ 50 mL/min Not pregnant lactate Negative pregnancy test Fertile patient must use effective contraception least 3 month completion study therapy No active cancer No untreated and/or uncontrolled cardiovascular comorbid condition Patients significant cardiac history , even control , LVEF &gt; 50 % No uncontrolled diabetes Must accessible treatment followup PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior cytotoxic chemotherapy IGF1R target agent SCLC At least 3 week since prior radiotherapy neurological sit No prior radiotherapy lung Prior surgery allow provide wound heal occur At least 14 day since prior major surgery No concurrent investigational agent therapy No concurrent anticancer treatment No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>combine type small cell lung cancer</keyword>
	<keyword>fusiform type small cell lung cancer</keyword>
	<keyword>polygonal type small cell lung cancer</keyword>
	<keyword>lymphocyte-like type small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>